These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 32544169)

  • 41. Heterogeneous mutational profile and prognosis conferred by TP53 mutations in appendiceal mucinous neoplasms.
    Zhu X; Salhab M; Tomaszewicz K; Meng X; Mathew C; Bathini V; Switzer B; Walter O; Cosar EF; Wang X; Lambert LA; Hutchinson LM
    Hum Pathol; 2019 Mar; 85():260-269. PubMed ID: 30458197
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Next‑generation sequencing‑based detection of EGFR, KRAS, BRAF, NRAS, PIK3CA, Her‑2 and TP53 mutations in patients with non‑small cell lung cancer.
    Jing C; Mao X; Wang Z; Sun K; Ma R; Wu J; Cao H
    Mol Med Rep; 2018 Aug; 18(2):2191-2197. PubMed ID: 29956783
    [TBL] [Abstract][Full Text] [Related]  

  • 43. PI3K inhibitor enhances the cytotoxic response to etoposide and cisplatin in a newly established neuroendocrine cervical carcinoma cell line.
    Lai ZY; Yeo HY; Chen YT; Chang KM; Chen TC; Chuang YJ; Chang SJ
    Oncotarget; 2017 Jul; 8(28):45323-45334. PubMed ID: 28484083
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Patterns of recurrence and survival in neuroendocrine cervical cancer.
    Stecklein SR; Jhingran A; Burzawa J; Ramalingam P; Klopp AH; Eifel PJ; Frumovitz M
    Gynecol Oncol; 2016 Dec; 143(3):552-557. PubMed ID: 27645621
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Adoptive Immune-Cell Therapy for the Treatment of Neuroendocrine Carcinoma of the Uterine Cervix.
    Goto S; Terao Y; Kamigaki T; Takimoto R; Naitoh K; Makita K; Yasumoto K; Okada S; Takizawa K; Yokomichi N; Suzuki N; Takeda S
    Anticancer Res; 2020 Aug; 40(8):4741-4748. PubMed ID: 32727800
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Mixed Mesonephric Adenocarcinoma and High-grade Neuroendocrine Carcinoma of the Uterine Cervix: Case Description of a Previously Unreported Entity With Insights Into Its Molecular Pathogenesis.
    Cavalcanti MS; Schultheis AM; Ho C; Wang L; DeLair DF; Weigelt B; Gardner G; Lichtman SM; Hameed M; Park KJ
    Int J Gynecol Pathol; 2017 Jan; 36(1):76-89. PubMed ID: 27532149
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Loss of 1p36.33 Frequent in Low-Grade Serous Ovarian Cancer.
    Van Nieuwenhuysen E; Busschaert P; Laenen A; Moerman P; Han SN; Neven P; Lambrechts D; Vergote I
    Neoplasia; 2019 Jun; 21(6):582-590. PubMed ID: 31054497
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Molecular abnormalities associated with endocrine tumors of the uterine cervix.
    Wistuba II; Thomas B; Behrens C; Onuki N; Lindberg G; Albores-Saavedra J; Gazdar AF
    Gynecol Oncol; 1999 Jan; 72(1):3-9. PubMed ID: 9889022
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Exploring a Better Adjuvant Treatment for Surgically Treated High-Grade Neuroendocrine Carcinoma of the Cervix.
    Wang R; Xiao Y; Ma L; Wu Z; Xia H
    Gynecol Obstet Invest; 2022; 87(6):398-405. PubMed ID: 36273460
    [TBL] [Abstract][Full Text] [Related]  

  • 50. The association of genomic lesions and PD-1/PD-L1 expression in resected triple-negative breast cancers.
    Barrett MT; Lenkiewicz E; Malasi S; Basu A; Yearley JH; Annamalai L; McCullough AE; Kosiorek HE; Narang P; Wilson Sayres MA; Chen M; Anderson KS; Pockaj BA
    Breast Cancer Res; 2018 Jul; 20(1):71. PubMed ID: 29996881
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Integrated clinicomolecular characterization identifies RAS activation and CDKN2A deletion as independent adverse prognostic factors in cancer of unknown primary.
    Bochtler T; Reiling A; Endris V; Hielscher T; Volckmar AL; Neumann O; Kirchner M; Budczies J; Heukamp LC; Leichsenring J; Allgäuer M; Kazdal D; Löffler H; Weichert W; Schirmacher P; Stenzinger A; Krämer A
    Int J Cancer; 2020 Jun; 146(11):3053-3064. PubMed ID: 31970771
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Cervical small cell neuroendocrine tumor mutation profiles via whole exome sequencing.
    Cho SY; Choi M; Ban HJ; Lee CH; Park S; Kim H; Kim YS; Lee YS; Lee JY
    Oncotarget; 2017 Jan; 8(5):8095-8104. PubMed ID: 28042953
    [TBL] [Abstract][Full Text] [Related]  

  • 53. GNAS(R201H) and Kras(G12D) cooperate to promote murine pancreatic tumorigenesis recapitulating human intraductal papillary mucinous neoplasm.
    Taki K; Ohmuraya M; Tanji E; Komatsu H; Hashimoto D; Semba K; Araki K; Kawaguchi Y; Baba H; Furukawa T
    Oncogene; 2016 May; 35(18):2407-12. PubMed ID: 26257060
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Spectrum of neuroendocrine carcinomas of the uterine cervix, including histopathologic features, terminology, immunohistochemical profile, and clinical outcomes in a series of 50 cases from a single institution in India.
    Rekhi B; Patil B; Deodhar KK; Maheshwari A; A Kerkar R; Gupta S; Tongaonkar HB; Shrivastava SK
    Ann Diagn Pathol; 2013 Feb; 17(1):1-9. PubMed ID: 22534245
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Clinical implication of oncogenic somatic mutations in early-stage cervical cancer with radical hysterectomy.
    Watanabe T; Nanamiya H; Kojima M; Nomura S; Furukawa S; Soeda S; Tanaka D; Isogai T; Imai JI; Watanabe S; Fujimori K
    Sci Rep; 2020 Oct; 10(1):18734. PubMed ID: 33127935
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Precise Classification of Cervical Carcinomas Combined with Somatic Mutation Profiling Contributes to Predicting Disease Outcome.
    Spaans VM; Trietsch MD; Peters AA; Osse M; Ter Haar N; Fleuren GJ; Jordanova ES
    PLoS One; 2015; 10(7):e0133670. PubMed ID: 26197069
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Specific Genomic Alterations in High-Grade Pulmonary Neuroendocrine Tumours with Carcinoid Morphology.
    Cros J; Théou-Anton N; Gounant V; Nicolle R; Reyes C; Humez S; Hescot S; Thomas de Montpréville V; Guyétant S; Scoazec JY; Guyard A; de Mestier L; Brosseau S; Mordant P; Castier Y; Gentien D; Ruszniewski P; Zalcman G; Couvelard A; Cazes A
    Neuroendocrinology; 2021; 111(1-2):158-169. PubMed ID: 32015233
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Absence of GNAS and BRAF mutations but presence of KRAS mutation in urachal adenocarcinoma.
    Hang JF; Pan CC
    Pathology; 2017 Apr; 49(3):316-317. PubMed ID: 28285720
    [No Abstract]   [Full Text] [Related]  

  • 59. Clinical Impact of KRAS and GNAS Analysis Added to CEA and Cytology in Pancreatic Cystic Fluid Obtained by EUS-FNA.
    Faias S; Duarte M; Albuquerque C; da Silva JP; Fonseca R; Roque R; Dias Pereira A; Chaves P; Cravo M
    Dig Dis Sci; 2018 Sep; 63(9):2351-2361. PubMed ID: 29796909
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Analysis of p53, K-ras-2, and C-raf-1 in pulmonary neuroendocrine tumors. Correlation with histological subtype and clinical outcome.
    Przygodzki RM; Finkelstein SD; Langer JC; Swalsky PA; Fishback N; Bakker A; Guinee DG; Koss M; Travis WD
    Am J Pathol; 1996 May; 148(5):1531-41. PubMed ID: 8623922
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.